Tuesday, July 23, 2019
News
NEWS HOME
»
PRESS RELEASES

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPa Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
  SocialTwist Tell-a-Friend  
   


Date: 18-06-2019 12:43PM
Source: Boehringer Ingelheim
Category: Business/ Finance, Pharmaceutical, General, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Nantes, France & Ingelheim, Germany

Business Wire India

  • First-in-class checkpoint inhibitor BI 765063 licensed to and being developed under a collaboration agreement between Boehringer Ingelheim and OSE Immunotherapeutics
  • Clinical Trial Authorization and dosing of the first patient triggers a total of €15 million milestone payments from Boehringer Ingelheim to OSE Immunotherapeutics


Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumors. The Phase 1 study is a dose finding study of BI 765063, a myeloid checkpoint inhibitor, administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a T-lymphocyte checkpoint inhibitor.

“We are very pleased with the progress achieved on BI 765063’s program and having the first patient dosed marks a significant milestone in the product’s development. The advancement of a myeloid cell checkpoint blocking monoclonal antibody into the clinic exemplifies Boehringer Ingelheim’s commitment to the next wave of innovation in cancer immunology therapies, with the goal of meaningfully improving outcomes for patients with difficult-to-treat cancers” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head, Cancer Immunology & Immune Modulation Research at Boehringer Ingelheim.

“We are excited to begin first-in-human testing with this novel SIRPα-targeting compound, which we believe has first-in-class potential in the treatment of solid tumors,” said Alexis Peyroles, chief executive officer of OSE Immunotherapeutics. “This marks one of many anticipated milestones in the collaboration agreement with our partner Boehringer Ingelheim, and we look forward to advancing rapidly this potentially transformative treatment through the clinic. Milestones such as this one for the novel compounds our R&D teams develop have provided OSE with a stable financial base to grow steadily our first-in-class immuno-oncology pipeline.”

The study is conducted by OSE Immunotherapeutics as part of a collaboration and license agreement under which Boehringer Ingelheim obtained exclusive rights to BI 765063. Under the terms of the collaboration and license agreement, the clinical trial authorization obtained in March 2019 and dosing of the first patient in this Phase 1 trial triggers milestone payments of a total of €15 million to OSE Immunotherapeutics from Boehringer Ingelheim. This trial aims to characterize safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the immunotherapy in patients with advanced solid tumours.

Please click on the link for “Notes to the Editors” and “References”

http://www.boehringer-ingelheim.com/press-release/bi-765064-sirp-antibody-phase-i-started



CONTACTS :

Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
press@boehringer-ingelheim.com
P: +49 6132 77-90815
M: + 49 151 150 20 690
www.boehringer-ingelheim.com

More Press Releases

Alibaba.com Opens Platform to Empower U.S. Small Businesses to Sell to the World

Sumitomo SHI FW Wins Contract for CFB Boiler in Taiwan

Merck Foundation Launches First 'Merck Foundation Health Media Training' and Media and Fashion Awards in Partnership With the First Lady of Malawi to Break Infertility Stigma in the Country

Peace and Tranquility Enhanced at Hiranandani Parks, Oragadam With Renovation of Sri Agatheeswarar Temple

Avail Multi-Deposit Facility by Investing in Bajaj Finance FD

Lumileds Wins Worldwide Permanent Injunction Against Elec-Tech International Co., Ltd. for Intellectual Property Infringement

Strand Life Sciences Joins the Global Diagnostics Network (GDN)

IDEMIA Will Present Its H1 2019 Financial Results to Investors on July 30, 2019

S. Bagchi Classes, the Premier Platform for the Aspirants of IIT, WBJEE and Medical Examinations

Antibiotic Residues in Milk Put Indian iGen at Risk: F1rst Study

Vantage Business School to Commence PGDBM Course Specialising in Wealth Management

IBC Celebrates Young Talent in the Industry

Messe Frankfurt Acquires License to Organise Busworld in India, Further Strengthening Its Mobility Segment

Hyundai Motor India Organizes Mega Experience Service Camp

Secure Your Retirement With a Bajaj Finance Fixed Deposit

Moody’s Analytics Wins Credit Data Provider of the Year at Risk Technology Awards

Bajaj Finserv Offers 74 Types of Pocket Insurance to Plan for Life’s Not so Nice Surprises

U.N. Environment Programme Urged to Protect Nature and Humankind from Electromagnetic Fields (EMF)

GEFCO Group Looks to Strengthen India Operations; Appoints Prasanna Kumar M.V. As Chief Executive Officer and Managing Director of GEFCO INDIA

SAS India Recognised as One of the Best Workplaces in 2019

Turner’s Aviation Journey: Kempegowda International Airport, Bengaluru

Sony Pictures Networks India Inaugurates the 24th Community Water Centre in Maharashtra

Hiranandani Parks, Oragadam, Chennai an Ideal Location for Sports Enthusiasts: Dr Niranjan Hiranandani, CMD, Hiranandani Communities

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Global Convenience Retail Technology Leader PDI Opens Regional Center of Excellence in Bangkok

Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease

Study Investigates the Ability of Continuous Noninvasive Hemoglobin Monitoring with Masimo SpHb® to Reflect Acute Hemodilution During Incremental Fluid Administration

Raid to Seize Illegal ISI Helmets at Ghaziabad Factory

Schlumberger Announces Second-Quarter 2019 Results

United Technologies Corporation Selects L&T Technology Services as a Strategic Partner for Collins Aerospace

Check out 7 Exclusive Variants of Bajaj Finserv RBL Bank SuperCard

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Amarnath Yatra briefly halted in Kashmir...
Left not against Sabarimala or its belie...
UP: Woman accuses husband of giving trip...
India did not request Trump to mediate i...
I-T raid at Kuldeep Bishnoi's residence,...
Kingpin of drugs trade in state yet to b...
More...    
 
 Top Stories
Kiara welcomes Aditya Seal in 'Indo... 
Opposition uproar in Parliament, go... 
2 Australians held in Bali for coca... 
nubia Red Magic 3: Smooth gaming, g... 
Top 5 Ashes encounters in the last ... 
ACB books ex-J&K Bank chairman, kin... 
Pakistan knew about Osama's presenc... 
Delhi court summons Kejriwal in def...